Nantahala Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Nantahala Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.65M	Sell	67,282 -307,718	-82%	-$17.8M	0.21%	95
2025 Q4	$15.5M	Hold	375,000	–	–	0.51%	48
2025 Q3	$14.8M	Buy	+375,000	New	+$9.58M	0.51%	47
2024 Q1	–	Sell	-328,433	Closed	-$3.42M	–	129
2023 Q4	$3.42M	Sell	328,433 -8,429	-3%	-$93.1K	0.2%	80
2023 Q3	$4.6M	Buy	336,862 +24,362	+8%	+$307K	0.39%	56
2023 Q2	$3.79M	Buy	+312,500	New	+$3.55M	0.37%	58

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nantahala Capital Management's DNTH Position: Q1 2026 in Review

Nantahala Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 82% in Q1 2026, selling an estimated $17.8M and leaving 67,282 shares worth $5.65M. The position accounts for 0.21% of the portfolio, ranked #95.

Nantahala Capital Management first reported a position in DNTH in Q2 2023 and has held it in 6 quarters since. The position peaked at $15.5M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

Nantahala Capital Management held 67,282 shares of Dianthus Therapeutics worth $5.65M as of Q1 2026.
Nantahala Capital Management sold 307,718 Dianthus Therapeutics shares in Q1 2026, an estimated $17.8M.
Dianthus Therapeutics made up 0.21% of Nantahala Capital Management's portfolio in Q1 2026, its #95 holding.
Nantahala Capital Management first reported a position in Dianthus Therapeutics in Q2 2023 and has held it in 6 quarters since.
Nantahala Capital Management's Dianthus Therapeutics position peaked at $15.5M in Q4 2025.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Nantahala Capital Management's 13F filing for Q1 2026, filed 15 May 2026.